TID

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

Retrieved on: 
火曜日, 5月 28, 2024
Patient, European Renal Association, Pharmacokinetics, ATP, SAD, AKI, Acute kidney injury, Kidney disease, LOS, Dialysis, Index, DGF, BID, Therapy, Histology, Safety, NGAL, Chronic kidney disease, MD, Congress, Animal, CKD, Rat, Incidence, Biomarker, Kidney, Nanotechnology, Poster, TID, Hyperphosphatemia, Aes, Sevelamer, ERA, Pharmaceutical industry

LOS ALTOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that several presentations were delivered on the Company’s two product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress. OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator initially targeting acute kidney injury (AKI).

Key Points: 
  • UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator initially targeting acute kidney injury (AKI).
  • This data compliments our previously reported data in the intravenous (IV) form of UNI-494.
  • The study concluded that UNI-494 is a potential candidate for prevention of delayed graft function (DGF) and other clinical conditions resulting from AKI.
  • Oxylanthanum Carbonate (OLC) Presentation Details:
    Results: This oral presentation evaluated the effects of tenapanor and OLC on phosphate excretion in rats.

Microchip Expands its Radiation-Tolerant Microcontroller Portfolio with the 32-bit SAMD21RT Arm® Cortex®-M0+ Based MCU for the Aerospace and Defense Market

Retrieved on: 
木曜日, 5月 16, 2024
JAXA, Radiation, Artemis 2, Orbit, Integrated circuit, COTS, Field-programmable gate array, Hertz, SPI, IDE, Digital, MPLAB, SAMD21, LIN, Immunity, Watchdog timer, ADC, Analog, AI, Lunar Gateway, Serial communication, DAC, MCU, WDT, Communication, Artemis, Absorbed dose, MCHP, TID, LEO, RTC, Knowledge, TCC, Microchip Technology, Space Launch System, History, Family, DMAC, RT, Orion (spacecraft)

Designers require electronic components that meet stringent radiation and reliability standards to operate in the harsh environments found in space.

Key Points: 
  • Designers require electronic components that meet stringent radiation and reliability standards to operate in the harsh environments found in space.
  • Microchip Technology (Nasdaq: MCHP) today announces the SAMD21RT , a radiation-tolerant (RT) Arm® Cortex®-M0+ based 32-bit microcontroller (MCU) in a 64-pin ceramic and plastic package with 128 KB Flash and 16 KB SRAM.
  • Designed for space-constrained applications where size and weight are of critical importance, the SAMD21RT is available in a small footprint of 10 mm × 10 mm.
  • The SAMD21RT device builds on Microchip’s existing family of SAMD21 MCUs, which is widely used in industrial and automotive markets.

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

Retrieved on: 
水曜日, 5月 15, 2024
PBS, Patient, PD, Kidney disease, LOS, Dialysis, FDA, National Kidney Foundation, Therapy, Snack, Chronic kidney disease, MD, CKD, Incidence, Șaeș, Poster, Tablet, TID, Hyperphosphatemia, NKF, OLC, BL, Aes, Meal, Quality of life, PB, Pharmaceutical industry

LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), were presented at the National Kidney Foundation (NKF) Spring Clinical Meeting. OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).

Key Points: 
  • LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), were presented at the National Kidney Foundation (NKF) Spring Clinical Meeting.
  • OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
  • “The NKF Spring Clinical Meeting was an important meeting for Unicycive as we were able to present data from the OLC bioequivalence study and our second poster was featured as a top-rated submission,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • Our data confirms that OLC is bioequivalent to lanthanum carbonate (LC) by showing similar outcomes in both groups with respect to mean change in urinary phosphate excretion.

Radiation-Tolerant DC-DC 50-Watt Power Converters Provide High-Reliability Solution for New Space Applications

Retrieved on: 
火曜日, 5月 7, 2024
QML, Radiation, Microchip Technology, LEO, Internet of things, Integrated circuit, MCHP, DC-DC, Family, Field-programmable gate array, EMI, TID, RT, Linear energy transfer, COTS

There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.

Key Points: 
  • There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.
  • The off-the-shelf LE50-28 family of power converters are designed to meet MIL-STD-461.
  • This series provides flexibility to parallel up to four power converters to reach 200-Watts.
  • Designed to serve 28V bus systems, the LE50-28 isolated DC-DC power converters can be integrated with Microchip’s PolarFire® FPGAs, microcontrollers and LX7720-RT motor control sensor for a complete electrical system solution.

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Retrieved on: 
火曜日, 4月 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Southern California, FDA, Idiopathic pulmonary fibrosis, University, Vital capacity, FVC, Safety, Survival, IPF, CNS, Incidence, Patient, TID, Pirfenidone, Caregiver, Aes, Central nervous system, PRTC, Biomarker, Pharmacology, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).
  • This PK profile and the resulting favorable tolerability have been demonstrated across multiple clinical trials in more than 400 individuals.
  • PureTech believes the results of the Phase 2b trial, together with an additional Phase 3 trial, could serve as the basis for registration in the U.S. and other geographies.
  • PureTech would like to extend its gratitude to those participating in the ELEVATE IPF trial, especially the people living with IPF and their caregivers, the clinical trial sites, investigators and advocacy groups.

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
月曜日, 4月 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

ESS Tech, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 3月 13, 2024
Other Manufacturing, Environment, Technology, Other Energy, Engineering, Alternative Energy, Manufacturing, Green Technology, Energy, Batteries, Nexus, Energy Centre, Forward, Interest, EW, Partnership, Telephone, Reefer ship, Honeywell, EDT, TID, Contingency, BWP, Investment, Portland General Electric, ESS, Renewable energy

ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE:GWH), a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE:GWH), a leading manufacturer of long-duration energy storage systems (LDES) for commercial and utility-scale applications, today announced financial results for its fourth quarter and full year ended December 31, 2023.
  • At the end of 2023, ESS successfully “lifted” its first Energy Center™ (EC), a key milestone in the manufacturing process.
  • ESS will hold a conference call on Wednesday, March 13, 2024 at 5:00 p.m. EDT to discuss financial results for its fourth quarter and full year ended December 31, 2023.
  • A live webcast of the conference call will be available on ESS’ Investor Relations website at http://investors.essinc.com/ .

VPT Announces Release of the New 1600W, GaN-based SGRBX DC-DC Converter

Retrieved on: 
水曜日, 3月 13, 2024
Radiation, Gallium nitride, Satellite, Sale, VPT, TID, EMI, Engineering, HEI, Spaceflight, HEICO, DC-DC, Electric motor

BLACKSBURG, Va., March 13, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE: HEI), announces the release of the first-ever configurable box solution featuring state-of-the-art GaN technology: the SGRBX .

Key Points: 
  • BLACKSBURG, Va., March 13, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE: HEI), announces the release of the first-ever configurable box solution featuring state-of-the-art GaN technology: the SGRBX .
  • Housing up to four award-winning SGRB DC-DC converter slices within its framework, the SGRBX delivers up to 1600 watts of output power.
  • Utilizing the SGRB's advanced fixed frequency, reduced voltage switching topology, the SGRBX has extremely low input and output noise.
  • VPT is formally introducing the SGRBX at Satellite 2024 March 18th-21st in Washington, DC, featuring an SGRBX demo box solution at VPT's booth, #2755.

VPT Announces Release of the New 1600W, GaN-based SGRBX DC-DC Converter

Retrieved on: 
水曜日, 3月 13, 2024
Radiation, Gallium nitride, Satellite, Sale, VPT, TID, EMI, Engineering, HEI, Spaceflight, HEICO, DC-DC, Electric motor

BLACKSBURG, Va., March 13, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE: HEI), announces the release of the first-ever configurable box solution featuring state-of-the-art GaN technology: the SGRBX .

Key Points: 
  • BLACKSBURG, Va., March 13, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE: HEI), announces the release of the first-ever configurable box solution featuring state-of-the-art GaN technology: the SGRBX .
  • Housing up to four award-winning SGRB DC-DC converter slices within its framework, the SGRBX delivers up to 1600 watts of output power.
  • Utilizing the SGRB's advanced fixed frequency, reduced voltage switching topology, the SGRBX has extremely low input and output noise.
  • VPT is formally introducing the SGRBX at Satellite 2024 March 18th-21st in Washington, DC, featuring an SGRBX demo box solution at VPT's booth, #2755.

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Retrieved on: 
土曜日, 2月 24, 2024
BTK, QPM, BID, AAAAI, Week, Omalizumab, TID, News, Prurigo nodularis, Asthma, Swelling, IgG4-related disease, Skin, Oral medicine, UAS7, Patient, CSU, Disease, Itch, LSM, ITT, American Academy, Pharmaceutical industry

Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.

Key Points: 
  • Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines.
  • Significant reduction from baseline to week 12 in weekly urticaria activity score (UAS7) [LSM -17.95 vs -11.20, respectively; p=0.0116].
  • Significant reduction from baseline to week 12 in weekly hives severity score (HSS7) [LSM -8.31 vs -4.89; p
  • Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.